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Background: People with cancer receive regular structured follow up after initial treatment, usually by a specialist
in a cancer centre. Increasing numbers of cancer survivors prompts interest in alternative structured follow-up
models. There is worldwide evidence of increasing interest in delivering cancer follow-up using technology. This
review sough evidence supporting the use of technology in cancer follow-up from good quality randomised
controlled trials.
Method: A search strategy was developed to identify randomised controlled trials and reviews of randomised trials
of interventions delivering some aspect of structured cancer follow-up using new technologies. Databases searched
were: All EBM Reviews; Embase; Medline (No Revisions); Medline (Non-Indexed Citations), and CAB Abstracts. Included
articles were published in English between 2000 and 2014. Key words were generated by the research question. Papers
were read independently and appraised using a standardised checklist by two researchers, with differences being
resolved by consensus [J Epidemiol Community Health, 52:377–384, 1998]. Information was collected on the purpose,
process, results and limitations of each study. All outcomes were considered, but particular attention paid to areas
under consideration in the review question.
Results: The search strategy generated 22879 titles. Following removal of duplicates and abstract review 17 full papers
pertaining to 13 randomised controlled studies were reviewed. Studies varied in technologies used and the elements
of follow-up delivered, length of follow-up, tumour type and numbers participating. Most studies employed only standard
telephone follow-up. Most studies involved women with breast cancer and included telephone follow-up. Together the
results suggest that interventions comprising technology had not compromised patient satisfaction or safety, as measured
by symptoms, health related quality of life or psychological distress. There was insufficient evidence to comment on
the cost effectiveness of technological cancer follow-up interventions.
Conclusions: Modern technology could deliver cancer follow-up that is acceptable and safe. More research is required
to develop cancer follow-up systems which exploit modern technology, which should be assessed using randomised
trials, with consistent outcomes, so that evidence on the acceptability, safety, cost effectiveness and impact in quality
of life of technological follow-up can accumulate and be made available to patients, professionals and policy makers.Background
Following the completion of their primary treatment for
cancer most patients enter a programme of structured
follow-up [1,2]. This is usually based in secondary care and
involves regular face to face consultations with specialist
cancer doctors; the precise frequency and content of
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focused on detecting recurrent disease, monitoring the
effects of treatment and providing ongoing support to
patients and their families and there is good evidence
that such care is valued by patients [4].
Current models of cancer follow-up are likely to be
unsustainable due to two important factors. Firstly, as the
population ages and treatment improves cancer prevalence
increases year on year [5]. This means that secondary care
services are tasked with the delivery of follow-up to an
increasing number of patients, and generally without
corresponding increase in resources [6]. Secondly, accessingral Ltd. This is an Open Access article distributed under the terms of the Creative
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especially those who live in remote and rural areas distant
from cancer centres [3]. Access difficulties to cancer
follow-up care could be one reason for the observation in
some areas of poorer outcomes in rural, compared to
urban, cancer patients [7]. In contrast modern technology
develops apace and offers increasing capability and func-
tionality to patients, professionals and health systems for
care delivery. Furthermore, the current population of can-
cer patients are increasingly familiar with technology and
consuming healthcare information and services on digital
platforms.
These issues together are the drivers to develop modern
and alternative models of cancer follow-up. To date these
have included varying the person delivering care (e.g. a
specialist nurse rather than a doctor) and varying the
location of cancer follow-up delivery (e.g. primary rather
than secondary care) [4]. Models of care that have been
subjected to randomised trials have included shared care,
nurse-led follow-up and GP-led follow-up, as well as shift-
ing the locus of care from hospital to the community [4].
A further alternative is to exploit the current innovative
technological environment and seek to understand how
digital means may be employed to deliver some or all
aspects of cancer follow-up care [8].
“Telemedicine” is defined as using technology to share
information over a distance between healthcare providers
(e.g. between GPs and hospital specialists), whereas “tele-
healthcare” is defined as using technology to provide
personalised healthcare to patients at a distance [9,10].
To date some investigators have incorporated the use
of land-line and mobile telephones into the delivery of
cancer follow-up [11-13].
As technology improves and cancer prevalence increases
interest in developing models of follow-up care that employ
novel technologies is certain to increase, for example
monitoring chemotherapy effects using smartphones
[12]. This systematic review was conducted to evaluate
existing evidence on the clinical safety, patient acceptabil-
ity, cost effectiveness and impact on quality of life from
telemedicine and telehealthcare where it has been applied
to cancer follow-up.
Methods
Search and identification of studies
The population of interest was adults with cancer. The
intervention was cancer follow up using technology and
the control usual care. Inclusion criteria were randomised
controlled studies published in English between 2000 and
2014, whose intervention included a telemedicine or tele-
healthcare element in the intervention. Studies not meeting
these criteria were excluded. The key outcomes of interest
were patient acceptability (satisfaction), clinical safety and
cost effectiveness.A search strategy based on key words to reflect the
review aim was designed in conjunction with a medical
librarian and is included as Additional file 1.
The searches were run in February 2014 on the following
databases: All EBM Reviews; Embase; Medline (No
Revisions); Medline (Non-Indexed Citations); CAB Ab-
stracts. Retrieved citations were exported to Refworks
(www.refworks.com). All identified titles were read and
those not meeting the inclusion criteria were excluded,
as were duplicates. Abstracts of the remaining studies
were screened against the inclusion criteria and full
articles were then retrieved.
Data collection
Critical appraisal of selected studies was undertaken
using a standardized checklist [14]. This was done by
two researchers (RD and SH). There was subsequent
discussion of assigned scores, and discussion and reso-
lution of any differences by consensus. Papers were
analyzed thematically considering particularly outcomes
that related to themes highlighted in the review question,
namely, clinical safety, patient acceptability, cost effective-
ness and impact on quality of life. Clinical safety was
defined as any outcome related to recurrent cancer or
mortality. Patient acceptability was defined as outcomes
reflecting how easily patients had found engaging with an
intervention, the extent to which it met their healthcare
needs, or how it impacted upon their satisfaction with
services. Cost effectiveness related to the reporting of
appropriate economic data. Quality of life related to any
outcomes reflecting symptoms or accepted or validated
measures of health related quality of life. Information
was collected on the purpose, process, results and limita-
tions of each study using a standardised data collection
template. All outcomes were considered with particular
attention paid to issues of patient acceptability and satis-
faction, clinical safety, cost and impact on quality of life.
Where quantitative data was presented it was tabulated as
p values, confidence intervals and effect sizes. A narrative
analysis of all papers was also conducted to identify the
emergent common and contrasting themes from the
reported studies.
Results
Study selection
Figure 1, a PRISMA diagram, displays the data for the
number of titles initially identified, then excluded along
with duplicates and the final number of randomised studies
identified and included.
Characteristics of included studies
Seventeen papers pertaining to 13 randomised studies
were included in the review. Tables 1 and 2 considers and
displays each of these studies in detail including terms of
Figure 1 PRISMA 2009 flow diagram.
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results, study quality score, measures used and detailed
results including effect sizes.
Included patients and countries
Of the thirteen included studies eight had been con-
ducted amongst women with breast cancer; one amongst
men with prostate cancer and one amongst people
with colorectal cancer [11,13,15-21]. Of the remaining
three, a Scottish study using mobile phones to monitor
symptoms was conducted in patients with breast, lung
or colorectal cancer currently undergoing chemother-
apy, a US study included patients with any solid
tumour or non-Hodgkin’s lymphoma who were cur-
rently undergoing chemotherapy and a Korean study of
cancer survivors who had reported severe fatigue
[12,22-24]. One study was conducted in the Netherlands
[17], one in Australia [21], two each in the UK [11,12,25],
and Canada [15,20], six in the USA [16,18,19,22,23,26]
and one in Korea [24]. The age ranges of patients were
not consistently recorded.Synthesis of key outcomes
Range of interventions and technologies employed
Of the 13 randomised studies the majority, seven, of the
interventions were relatively low-tech and had simply
employed standard telephone calls to cancer aftercare
recipients in their own homes, as an alternative to stand-
ard follow-up [11,13,16-19,21]. These calls were generally
delivered by specialist nurses. The content, duration and
frequency varied across studies. Calls were mainly sched-
uled, regular, and lasted approximately 30 minutes, and
delivered components of symptom monitoring, infor-
mation sharing, and emotional support. Two further
interventions employed remote symptom monitoring
using a smartphone/personal digital assistant (PDA)
[12,20]. A further intervention employed an automated
voice activated telephone response system to monitor
symptom severity [22,23]. One intervention comprised
a computer programme, completed by those in aftercare,
which provided the patient with information and assisted
decision making [15]. Participants were encouraged to
work through the computer programme prior to their face
Table 1 Details of included studies including critical appraisal scores
Study and location Patient
population
Intervention Control Length of
follow up
Study outcomes Results Critical
appraisal score
Beaver et al., 2009
Manchester, UK [11]
374 breast
cancer patients
Telephone follow up
by specialist nurses
Usual hospital care 24 months
(mean)
Psychological morbidity Equivalence trial - : no
difference between the
two groups
Study Quality – 8/10
Participant’s needs for
information
External validity – 2/3
Participant’s satisfaction Internal Validity
(bias) – 6/7
Clinical Investigations
ordered
Internal Validity
(selection bias) – 6/6
Time to detection of
recurrent disease
Power – 1/1
(Total – 23/27)
Beaver et al., 2009
(Economic evaluation)
Manchester, UK [25]
374 breast
cancer patients
Cost minimization
analysis of RCT above
- 24 months
(mean)
Primary: NHS resource use Telephone follow-up more
costly (mean difference £55
but telephone patients had
lower personal costs (mean
difference £47)
No score as cost
analysis
Secondary: patient, carer
and productivity courses
Davison and Degner,
2002 Vancouver,
Canada [15]
749 breast
cancer patients
Computer programme
providing information and
assisting decision making
Standard care only- asked
about decision making
before clinic appointment
One clinic visit Involvement in decision
making
Women in the intervention
group reporting playing a
more passive role.
Study Quality – 6/10
Patient satisfaction Patient satisfaction was
high in both groups
External validity – 2/3
Internal Validity
(bias) – 5/7
Internal Validity
(selection bias) – 4/6
Power – 0/1
(Total – 17/27)
Harrison et al., 2011
Sydney, Australia [21]
75 patients with
colorectal cancer
5 telephone calls from a
specialist colorectal nurse
in 6 months after discharge
Standard care 6 months Unmet supportive care
needs
No difference between the
groups for unmet needs and
health service utilization
Study Quality – 8/10
Health service utilization Quality of life scores higher
in the intervention group at
6 months
External validity – 2/3
Quality of life Internal Validity
(bias) – 5/7
Internal Validity
(selection bias) – 6/6
Power – 0/1
(Total – 21/27)
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Table 1 Details of included studies including critical appraisal scores (Continued)
Hegel et al., 2010
New Hampshire,
USA [16]
31 Breast
cancer patients
6 weekly session of
telephone delivered
problem solving
occupational therapy
Usual care 12 weeks Primary outcome: feasibility
of conducting the trial
Overall positive outcomes Study Quality – 8/10
Secondary outcomes:
functional, quality of life
and emotional status
External validity – 3/3
Internal Validity
(bias) – 5/7
Internal Validity
(selection bias) – 6/6
Power – 0/1
(Total – 20/20)
Kearney et al., 2008
Stirling, Scotland [12]
112 cancer
patients
Mobile phone-based
remote monitoring
during chemotherapy
Standard care 16 weeks Chemotherapy related
morbidity – 6 common
symptoms, nausea, vomiting,
fatigue, mucositis, hand-foot
syndrome and diarrhoea
Higher reports of fatigue
in the control group and
lower reports of hand-foot
syndrome in the control
group
Study Quality – 8/10
External validity – 1/3
Internal Validity
(bias) – 5/7
Internal Validity
(selection bias) – 6/6
Power – 0/1
(Total – 20/27)
Kimman et al.,
2011 Maastricht,
Netherlands [17]
299 women
with breast
cancer
Nurse led telephone
follow up or
Hospital follow up or
hospital follow up
plus EGP
18 months Health related quality of
life (HRQoL)
No difference between
the two groups
Study Quality – 8/10
Nurse led telephone
follow up plus educational
group programme (EGP)
Secondary measures
included role and emotional
functioning and feelings of
control and anxiety
External validity – 2/3
Internal Validity
(bias) – 5/7
Internal Validity
(selection bias) – 6/6
Power – 1/1
(Total – 22/27)
Kimman et al.,
2011 Maastricht,
Netherlands [27]
299 women
with breast
cancer
Nurse led telephone
follow up or Nurse led
telephone follow up plus
educational group
programme (EGP)
Hospital follow up or
hospital follow up
plus EGP
18 months Quality adjusted life
gain (QALYs)
Hospital follow-up plus
EGP resulted in the highest
QALYs but has the highest
costs. Next best in terms of
costs and QALYs was nurse
led telephone follow up
plus EGP
No score as cost
analysis
Incremental cost-effectiveness
ratios (ICERs)
Kimman et al.,
2010 Maastricht,
Netherlands [13]
299 women
with breast
cancer
Nurse led telephone
follow up or
Hospital follow up or
hospital follow up
plus EGP
12 months Patient satisfaction Increased patient
satisfaction with access
to care in telephone
follow-up group. No
significant influence on
general patient satisfaction,
technical competence or
inter-personal aspects
Study Quality – 9/10
Nurse led telephone
follow up plus educational
group programme (EGP)
External validity – 2/3
Internal Validity
(bias) – 5/7
Internal Validity
(selection bias) – 5/6
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Table 1 Details of included studies including critical appraisal scores (Continued)
Power – 1/1
(Total – 22/27)
Kroenke et al.,
2010 Indiana,
USA [26]
405 cancer
patients
Centralized telecare
management by a
nurse-physican specialist
team coupled with
home-based symptom
monitoring by interactive
voice recording or internet
Usual care 12 months Depression Pain Improvements in pain
and depression for the
intervention group
Study Quality – 8/10
External validity – 2/3
Internal Validity
(bias) 6/7-
Internal Validity
(selection bias) – 6/6
Power – 1/1 (Total –
23/27)
Marcus et al., 2009
Colorado, USA [18]
304 breast
cancer patients
16 session telephone
counselling post treatment
Resource directory for
breast cancer was
given to each patient
18 months Distress No difference for distress
and depression
Study Quality – 8/10
Depression Need for clinical referral –
depression and distress
reduced by 50% in the
intervention group for
dichotomized end points
External validity – 2/3
Sexual dysfunction Effects found for personal
growth and sexual
dysfunction in the
intervention group
Internal Validity
(bias) – 5/7
Personal growth Internal Validity – 5/6
(selection bias)
Power – 0/1
(Total – 20/27)
Matthew et al., 2007
Toronto, Canada [20]
152 prostate
cancer patients
PDA survey followed
by paper
Paper followed
by PDA survey
30 mins Survey was monitoring
health-related quality of life
but outcomes looked at
assessment of data quality
and feasibility
Internal consistency similar Study Quality – 8/10
PDA followed by PDA
survey. (3 groups)
Test re-test reliability
confirmed
External validity – 3/3
Data from two modalities
strongly correlated.
Internal Validity
(bias) – 5/7
Fewer missed items for
the PDA
Internal Validity
(selection bias) – 5/6
More preferred using the
PDA or had no preference.
PDA found easy to use
Power – 0/1
(Total – 21/27)
Age did not correlate
with difficulty using PDA
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Table 1 Details of included studies including critical appraisal scores (Continued)
Sandgren et al.,
2003 North Dakota,
USA [19]
222 women
with breast
cancer
6×30 min telephone
therapy sessions that
involved either cancer
education or emotional
expressions
Standard care 5 months Perceived control Cancer education group
reported greater perceived
control compared to
standard care
Study Quality – 7/10
Mood
Quality of life No difference for mood
or quality of life
External validity – 2/3
Internal Validity
(bias) – 5/7
Internal Validity
(selection bias) – 6/6
Power – 1/1
(Total – 21/27)
Sikorski et al., 2009
Michigan, USA [22]
486 cancer
patients
Automated voice response
symptom reporting
Nurse assisted symptom
management via the
telephone
6 telephone
contacts over
8 weeks
Severity of cancer symptom
at intake interview and at
first intervention contact
Patient in the AVR group
reported more severe
symptoms. There was a
variation with age with
older patients reporting
more severity of symptoms
to the nurse
Study Quality – 9/10
External validity - 2/3
Internal Validity
(bias) – 5/7
Internal Validity
(selection bias) – 6/6
Power – 0/1
(Total – 22/27)
Sikorskii et al., 2007
Michigan, USA [23]
435 cancer
patients
Automated telephone
symptom management
Nurse-assisted symptom
management
10 weeks Severity of cancer symptoms,
demographic data and
co-morbidities
Reduction in symptom
severity in both groups. Lung
cancer patients with greater
symptom severity withdrew
from the ATSM group
Study Quality – 8/10
External validity – 2/3
Internal Validity
(bias) – 5/7
Internal Validity
(selection bias) – 6/6
Power – 1/1
(Total – 22/27)
Yun et al. 2012 Seoul,
Korea [24]
273 cancer
patients
Internet based, individually
tailored cancer related
fatigue education program
Usual care 12 weeks Level of fatigue Education group reported
a reduction in fatigue,
decrease in HADS anxiety
score, increase in global
QoL score and emotional,
cognitive and social
functioning of EORTIC
QLQ-C30
Study Quality – 8/10
Quality of Life, Anxiety
and depression
External validity – 1/3
Internal Validity
(bias) – 4/7
Internal Validity
(selection bias) – 6/6
Power – 1/1
(Total – 20/27)
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Table 2 Details of intervention, outcomes, measures used and results
Study Intervention Primary and secondary outcomes Measures used Results including statistical values
Beaver et al. (2009) [11,25] Telephone follow up by
specialist nurses
Psychological Morbidity State-trait anxietntdy inventory No difference for psychological morbidity
Participant’s need for information General Health Questionnaire Patients in telephone group more satisfied
(intention to treat p < 0.001)
Participants’ satisfaction No difference for information needs
Clinical investigations ordered No difference for clinical investigations
Time to detection of recurrent disease Recurrences :- no differences between the two
groups p = 0.295% CI (−3.33-2.07) – equivalence
demonstrated. 28)
Davison et al. (2002) [15] Computer programme
providing information
and assisting decision
making
“Extent to which women achieved their
preferred decisional roles”
Control Preferences Scale (CPS) Intervention group was more passive in decision
making than planned. (p < 0.0001)
Patient satisfaction Patient Satisfaction Questionnaire (PSQ) More women over 50 opted to play a more
passive role. (p= > 0.002)
No difference found for the two groups for
patient satisfaction. Both groups reported
high levels
Harrison et al. (2011) [21] 5 telephone calls from a
specialist colorectal nurse
in 6 months after discharge
Unmet supportive care needs SCNS-SF34 and FACT-C used for
unmet supportive care needs
and quality of life. CaSUN was
used to measure these two
outcomes at 6 months
No difference was found for unmet supportive
care needs at 6 months
Secondary outcomes: Patient asked to remember
health service use in a
telephone interview
“Observed effect size for supportive care needs
was 0.25“
Health service utilization Study was aiming for effect size of 0.75.
Quality of life Quality of life had improved by “twice as much”
in the intervention group at six months. (size of
difference = 5.7)
At 6 months in the intervention group; fewer
“presentations to emergency departments
(p = 0.23) and readmissions to hospital (p = 0.37)”
compared with the control group. Intervention
group patients had more contact with
“hospital-based, specialist based and community
services”. Differences for health service utilization
were not statistically significant
Hegel et al. (2010) [16] 6 weekly session of
telephone delivered
problem solving
occupational therapy
Feasibility of conducting a RCT including
patient satisfaction
Study recruitment and retention
data was gathered
“67% recruitment rate (31/46)”
Secondary outcomes: At 12 weeks participants
completed a satisfaction survey
“81% retention rate”
Functional quality of life “92% of those receiving the intervention were
“highly satisfied”
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Table 2 Details of intervention, outcomes, measures used and results (Continued)
Emotional status 92% reported it to be “helpful/very helpful”
97% if planned sessions of the intervention
were completed
Effect sizes were calculated for secondary outcomes
but “study was not powered to detect treatment
effects”. Main outcome was feasibility for study to
be repeated as larger scale RCT. No CIs quoted
Kearney et al. (2008) [12] Mobile phone-based
remote monitoring
during chemotherapy
“Chemotherapy-related morbidity”
of six symptoms
Electronic symptom questionnaire
completed by patients in control
and intervention group before
the start of chemotherapy and
prior to cycles 2, 3, 4 and 5
In the control group more report of fatigue
(CI = 1.04-5.05, P = 0.040) and lower reporting
of hand-foot syndrome (CI 0.17-0.92 P = 0.031)
Severity and distress of symptoms were no
different between the two groups except for
hand-foot syndrome in the intervention group.
(Severity CI −0.52 to −0.02 P = 0.033, Distress
CI −0.33 to −0.02, P = 0.028). Other differences
were not statistically significant
These were nausea, vomiting, fatigue,
mucositis, hand-foot syndrome and
diarrhoea”
Kimman et al., 2011 [17,27] Nurse led telephone
follow up or
Health-related quality of life (HRQoL) HRQoL: EORTC QLQ-C30 No difference between the two groups for
HRQoL. (P value = 0.42
Nurse led telephone
follow up plus educational
group programme (EGP)
Secondary outcomes: Role and emotional functioning:
EORTC QLQ-C30 subscales
Confidence interval of 95% for the “estimated
difference between mean HRQoL scores at 12
months after treatment” = −1.93-4.64)
Role and emotional functioning Anxiety: State Trait Anxiety Inventory
(STAI)
No differences between groups for all other
secondary outcomes (all p values > 0.05)
Feelings of control and anxiety Perceived feelings of control:
Mastery scale
Kroenke et al. (2010) [26] Centralized telecare
management by a nurse-
physican specialist team
coupled with home-based
symptom monitoring by
interactive voice recording
or internet
Depression and pain Measured at baseline and at 1, 3,
6 and 12 months. Depression
measured using the “20-item
Hopkins Symptom Checklist
(HSCL-20) and pain (BPI) severity
Greater improvements in pain (p < 0.001) and
depression (p < 0.001) in the intervention group.
Secondary outcomes: Health related quality of life: SF-12 Effect size “for between-group differences” at
12 months for pain were 0.39 (95% CI, 0.01-0.77)
and for depression, 0.41 (95% CI, 0.08-0.72)
Health-related quality of life “Quality of life – single item 0-10” No difference for health-related quality of life
and health-care use. Difference for “other pain
treatments” (p = 0.03).Disability Anxiety – “7-item Generalised
Anxiety Disorder scale”
Cointerventions “Physical symptom burden – 22-item
somatic symptom scale”
Self reported health care use Fatigue- “SF 36 vitality scale”
Disability – “3- item Sheehan
Disability Scale”
“Self-report health care use:
treatment survey”
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Table 2 Details of intervention, outcomes, measures used and results (Continued)
Marcus et al. (2009) [18] 16 session telephone
counselling post treatment
Cancer specific Distress Cancer specific Distress – Impact
of Event Scale (IES).
No differences found for depression and distress
unless end points were “dichotomized at
cutpoints suggestive of the need for clinical
referral”. A 50% reduction in depression and
distress was demonstrated in the intervention
group compared to the control. (p = 0.07)
Depression Depression – Centre for
Epidermiologic Studies
Depression Scale (CES-D)
“Significant effects” shown in sexual dysfunction
and personal growth for the intervention group
Sexual dysfunction Sexual Dysfunction – 25 items
(designed for study)
When endpoints dichotomized- no change in
the control group (depression: p = 0.41,
distress = 0.86). Intervention group (depression
p = 0.0007, distress p = 0.0007)
Personal Growth Personal growth – 5 items
(designed for study)
Group differences at 18 months were significant
Depression: p = 0.06 and Distress: p = 0.07
“with effect sizes of 0.23 and 0.24”
Sexual dysfunction: at 18 months, “significant
improvement intervention group” p = 0.04,
effect size = 0.23
Personal growth- both groups improved but
more in the intervention group. (At 18 months
p = 0.03, effect size =0.22)
Matthew et al. (2007) [20] PDA survey followed by paper Data quality International Prostate Symptom
Score (IPSS)
Internal consistency found to be high
PDA followed by PDA
survey. (3 groups)
Feasibility Patient Orientated Prostate cancer
Utility Survey (PORPUS) International
Index of Erectile Function-5 (IIEF-5)
either in paper or PDA forms
Test re-test reliability high. (p < 0.01)
Scores across modalities were correlated
demonstrating “concurrent validity (p < 0.01)”
No differences in levels of participation
Preference was highest for the PDA version of
the questionnaire. (58.6%)
Age did not have an impact on preference
(p = 0.12)
Age did not have an impact of difficulty using
PDA. (p = 0.08)
Confidence intervals quoted in the paper for
each of the data items within the questionnaire
Sandgren et al. (2003) [19] 6×30 min telephone
therapy sessions that
involved either cancer
education or emotional
expressions
Mood Quality of Life – Functional
Assessment of Cancer
Therapy-Breast Instrument
(FACT-B)
Cancer Education group – greater perceived
control (p < 0.01)
Quality of Life Mood – Profile of Mood States No difference for mood (p > 0.12) or quality of
life (p > 0.12) found
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Table 2 Details of intervention, outcomes, measures used and results (Continued)
Perceived control Perceived control – Perceived
Stress Scale
No CIs quoted- only standard deviations, means
and p values
Sikorskii et al. (2007) [22] Automated telephone
symptom management
Severity of symptoms 17 symptoms scored for severity –
designed for the study. Analysed
using a RASCH model
Both groups had a reduction in symptom
severity. No difference found between 2 groups
Effect sizes were almost the same for NASM
(0.56) and ATSM (0.59)
Sikorskii et al. (2009) [23] Automated voice response
symptom reporting
Severity of symptoms – difference
depending on mode of assessment
14 cancer related symptoms –
scored for severity. Designed
for the study
AVR group reported more severe symptoms
of “nausea, vomiting, diarrhoea, poor appetite,
pain and alopecia (p values less than 0.05)”
Varied with age with older patients reporting
higher severity in the nurse led group (effect
sizes greater or equal to 0.35”)
Yun et al. 2012 Seoul, Korea [24] Internet based, individually
tailored cancer related fatigue
education program
Level of fatigue Brief Fatigue Inventory (BFI) Intervention group reported an improvement
in fatigue with a significantly greater decrease
in BFI global score (−0.66 points, 95% CI −1.04
to −0.27), FSS total score (−0.49;95% CI, 0.78
to −0.21) and HADS score
Anxiety and depression Fatigue Severity Scale (FSS) Participants with moderate or greater fatigue
reported a significantly greater decrease in
HADS Anxiety score (−0.90; 95%CI, −1.51
to −0.29) as well as global quality of life (5.22;
95% CI, 0.93 to 9.50) and several functioning
scores of the EORTC QLQ_C30
Global quality of life Hospital Anxiety and Depression
Scale (HADS)
European Organisation for
Research and Treatment of
Cancer Quality of Life
Questionnaire C30
(EORTC QLQ_C30)
D
ickinson
et
al.BM
C
Cancer
2014,14:311
Page
11
of
16
http://w
w
w
.biom
edcentral.com
/1471-2407/14/311
Dickinson et al. BMC Cancer 2014, 14:311 Page 12 of 16
http://www.biomedcentral.com/1471-2407/14/311to face follow-up meeting, the aim being to enable them
to participate more fully in their subsequent follow-up
consultation [15]. One study sought to combine technolo-
gies in a centralised telephone management system oper-
ated by a specialist nurse [26]. Patients’ symptoms were
monitored in their own home using an internet based
application and/or a voice activated telephone helpline
with nurses telephoning patients back if symptoms
indicated this was required. The final study developed
Health Navigation, an Internet-based individually tai-
lored education programme for patients suffering from
cancer related fatigue. Participants had access to the
Health Navigation website and were guided through a
twelve week programme including sessions on energy
conservation, physical activity, nutrition, sleep hygiene, pain
control and distress management [24].
Patient acceptability/satisfaction
Data on patient satisfaction or acceptability was explicitly
reported in five of the trials [11,13,15,16,25]. Beaver et al.
reported that most women with breast cancer had
equivalent satisfaction with elements of cancer follow-
up received via technological means compared to usual
care [11,25]. Kimman et al. found that nurse-led telephone
follow-up after curative treatment for breast cancer re-
sulted in high satisfaction scores with the added potential
to reduce clinic visits [13]. In the study of symptom moni-
toring using paper or PDA surveys in men with prostate
cancer, most preferred using the PDA and found it easy to
use, and older age did not appear to be associated with
reports of difficulty in using the PDA [15]. A smaller feasi-
bility trial, reported that 92% of US women with breast
cancer who received 6 weeks of telephone delivered prob-
lem solving occupational therapy were highly satisfied
with the intervention [16]. There was no evidence from
the other studies that technological interventions led to
reduced patient satisfaction with follow-up care.
Clinical safety
Only one study reported on clinical safety [11,25]. It was
conducted amongst 374 women with breast cancer and
reported on time to detection of recurrence, with no signifi-
cant differences observed between intervention and control
groups.
Health-related quality of life
In a Scottish study of remote monitoring of symptoms
in patients undergoing chemotherapy intervention group
patients were less fatigued and reported more hand and
foot syndrome [12]. Similarly, in a US trial of chemotherapy
related symptom monitoring patients receiving symptom
monitoring via an automated telephone symptom monitor-
ing system reported more severe symptoms than those
receiving nurse assisted symptom management [22,23].After 10 weeks symptom severity, compared to baseline,
had reduced in both groups [23]. An Australian study of
patients with colorectal cancer receiving telephone follow-
up from a specialist nurse, quality of life scores were
higher in the intervention group at six months [21]. Inter-
vention participants in the Korean fatigue study [24] re-
ported a decrease in 12 week scores compared to baseline
in both the Brief Fatigues Inventory and Fatigue Severity
Scale as well as a reduction in anxiety and several func-
tioning scores of the EORTC-C30. However a study of
299 breast cancer patients in the Netherlands reported no
significant difference in the health-related quality of life
between the intervention group receiving telephone follow
up and the control group receiving hospital follow up
[17]. Taking these six trials together there was no evidence
of significantly increased psychological distress or reduced
quality of life in any of the intervention groups.
Health economic outcomes
Only two studies included any assessment of health eco-
nomic outcomes with only one study reporting specifically
on cost [25]. Beaver et al. conducted a cost minimisation
analysis of specialist nurse-led follow-up [25]. This con-
cluded that telephone follow-up was more costly for health
services, with patients receiving telephone follow–up
having approximately 20% more consultations than
those receiving hospital follow-up, in addition telephone
consultations were longer than clinic consultations and
requests for mammography or additional referrals were
greater in this group, however telephone follow-up was
less costly for patients [25]. It should be noted that many
of the health service costs related to training to deliver the
intervention, costs which would subsequently decline [25].
On the other hand, Dutch investigators, Kimman et al.,
[27] concluded that standard hospital follow-up plus an
educational group programme resulted in greater gain in
QALYs compared to telephone follow-up, but at consider-
able cost possibly due to the high level of contacts made
by the telephone follow-up group with specialised health-
care professionals and their costs of lost production [27].
In a subgroup analysis included within this study hospital
follow-up and an educational group programme was
found to be maximally cost effective in anxious patients.
Age, level of education, and chemotherapy did not influ-
ence cost-effectiveness [27]. Beaver et al. did not conduct
a sub-group analysis so comparisons could not be made at
this level [25].
In the other studies, whilst not formally reporting any
health economic evaluation, there was no evidence of in-
creased health care utilisation amongst recipients of the
intervention in fact one noted a significant reduction in
subsequent referrals for depression and distress amongst
304 US breast cancer patients that had received telephone
follow-up [18].
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A standard checklist was used to critically appraise the
included studies using standard criteria [14]. Scores are
shown in Table 1 and ranged from 17 to 23. One study
attracted a quality score of 6/10, mainly due to poor
expression of the study aims and description of the par-
ticipants [15]. Thus, these studies were generally of good
quality and reported to a high standard. In all cases the
researchers had addressed issues of internal validity and
recognised the issues created by not being able, in most,
cases to blind participants to the intervention. Most
studies failed to employ blinded data collection. In all
studies there was good recognition of, and controlling
of, potential confounding leading to high scores in this
domain. Most of the studies were, however, underpow-
ered with respect to clinical outcomes. The main issue
of quality with the study was a failure to demonstrate
external validity. Only four of the included studies included
information on non-respondents, generally reporting
that they were older and of lower educational status
[11,17,18,20]. This underscores the fact that technology
trials as currently reported exhibit considerable recruit-
ment bias. This was further illustrated by some of the
studies not reporting on non-respondents acknowledging
that this was a limitation and highlighting the fact that
they had, for example, recruited only urban or white
participants [15,18,28].
Discussion
Summary of evidence
The limited evidence available suggests that using tech-
nology for cancer follow-up is acceptable to patients and
clinically safe. However, there is currently insufficient
evidence to definitively state whether or not remote cancer
follow-up using technology is likely to be cost effective,
since most existing randomised trial evidence relates
to alternative models of follow-up using standard tele-
phone calls only. The results are important as a prompt
and guide to future research since, in the face an ageing
population and increasing number of cancer survivors,
the need for safe, acceptable and economically viable alter-
natives to current resource intensive cancer follow-up care
delivery models is urgent. Existing evidence suggests that
scheduled cancer follow-up can employ elements of tech-
nology without reducing patient satisfaction, compromising
safety, impairing quality of life or increasing psychological
distress.
Strengths and limitations
As far as we aware this is the first systematic review to
focus on the use of technology to deliver cancer follow-
up. The methods of the review were thorough and robust
and the authors have confidence that the search strategy
was suitably inclusive to identify most relevant studies.We chose to include only randomised controlled trials in
the review and did not include other studies types, such as
interrupted time series studies. This was principally due to
our concern that trials of new technologies are particularly
prone to selection bias (i.e. the recruitment of enthusiasts).
Whilst the randomised trial is not a panacea to this prob-
lem in technological research we believe that by restricting
our review to a method which explicitly addresses this
issue was the best approach. A further issue is that the
CONSORT statement which promotes quality in the
reporting has been widely accepted and implemented.
Furthermore randomised trials, in general, include harder
outcome. We believe our results have borne out our
approach.
The review was limited to studies written in English.
Thus it is possible that some studies conducted in other
parts of the world were missed. This is particularly so
when it is considered that many non-English speaking
countries, for example, Germany are key-players in techno-
logical innovation. We do think, however, that since English
is practically the “lingua franca” of medical research it is
unlikely that we have missed any major randomised trial
by employing this limitation. It does seem most likely that
these would have been published in a journal employing
the English language for which the search strategy was
exhaustive. Further support for this view can be obtained
from the fact that both trials currently registered on the
ISRCTN register of using technology in cancer follow-up
are in non-English speaking countries but fully described
and registered in English.
The majority of existing studies were conducted in the
developed world in women with breast cancer, a group
which will potentially represent the more enabled and
affluent end of the cancer survivorship spectrum. This
limits the extension of the current findings to other
settings, cancers and patient groups, emphasising the need
for further research. It could also be that there are patient
groups in whom it would be inappropriate to attempt to
utilise technology in their follow-up, an issue that the
current evidence goes no way toward identifying or ad-
dressing. Furthermore, there was insufficiently consistent
reporting within the studies of inclusion criteria with
respect to time since completion of treatment or stage
at diagnosis to draw meaningful conclusions with respect
to these parameters. A further limitation has occurred in
the synthesis and interpretation of the evidence. There
were surprisingly few randomised studies identified and
the majority used telephone follow-up only, with only a
few adopting more recent technological innovations such
as PDAs. Thus, given the increasing potential of modern
digital technologies the included interventions were rela-
tively simple and low-tech. Furthermore, the way in which
technology could enable patients to send information to
healthcare professionals has not yet been meaningfully
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aspects of follow-up care (recurrence monitoring, moni-
toring treatment effect, information provision) none were
comprehensive, and most used technology to deliver one
aspect of follow-up care as an adjunct to more traditional
follow-up models. Because of this direct comparison of
interventions was extremely difficult given the differ-
ent technologies, interventions and outcomes reported.
Nevertheless, we believe the current review provides
good evidence of the potential of technology to deliver
safe effective cancer follow-up in the future. The review
also highlights the need for future trials to seek to provide
definitive information on patient acceptability, clinical
safety and cost effectiveness.
Context with other literature
There is a growing recognition that cancer follow-up
services are increasingly stretched by a growing popu-
lation of cancer survivors [1,3,6]. This has prompted
researchers to develop alternative models of care which
have utilised different healthcare professionals in care
delivery and/or shifted the focus of care from hospital
to the community [4,29,30]. Despite, this, these models
will probably continue to consume a large and growing
amount of healthcare resource and still inconvenience
certain patient groups. The randomised studies included
within this review are striking in the respect that they
demonstrate that few mature complex interventions utilis-
ing technology, other than standard telephone calls, have
been developed to a standard sufficient for subjection
to a randomised controlled trial. The need to do this is,
perhaps, one of the key implications of our work.
There is an emerging vision that modern technologies,
evidenced by policy initiative worldwide, could potentially
enhance current models or offer other alternatives to the
future delivery of high quality cancer care [31-38]. There
is considerable evidence from other disease areas of using
modern technologies to good effect [39]. For example, text
messaging has been found to increase self-efficacy and
adherence to medication in young people with diabetes
and has been proven to be an effective aid to smoking
cessation [40,41]. Online systems which enable pa-
tients to access their own health records have enjoyed
some success as a means to educate patients and assist
in their self-management, for example, in the USA,
Kaiser Permanente’s My Health Manager has demon-
strated significant reductions in primary care contacts
[42]. The CHAMPION project has enabled disabled
adults to improve communication with healthcare pro-
fessionals by inputting information on their own care
needs into a database, for example, uploading a video
to demonstrate to clinical staff how they use their
communication devices [43]. However, there is now a
striking need to develop high quality and innovativetechnological interventions to support growing numbers
of people with cancer.
Inspection of the International Standard Randomised
Controlled Trial Number Register indicates that increas-
ing numbers of clinical trials of technological applications
to healthcare are occurring [44]. The register lists twenty-
three active trials on telehealth, telemedicine or ehealth,
including trials in men with prostate cancer and another
amongst patients with breast or colorectal cancer [45,46].
Nevertheless, this is surprisingly few randomised trials
given the explosion in technological innovation in recent
years. It could be that technology is evolving so fast that
potential innovative technological interventions become
outdated before they can mature sufficiently to be sub-
jected to randomised trials.
Conclusions
At the current time there are few well conducted ran-
domised trials exploring the role of digital and other
technologies in the delivery of structured cancer aftercare.
There is, however, some evidence that modern technolo-
gies can be used to safely and effectively deliver aspects of
structured cancer follow-up as an alternative or adjunct to
existing traditional models which require patients to travel
to tertiary cancer centres for face to face visits with a can-
cer specialist. Given the potential gains offered by digital
technology in terms of patient convenience and empower-
ment and reduction of resource use in cancer centres,
there is an urgent need for future cancer research to em-
brace the digital age and seek to integrate various different
technologies into innovative and comprehensive models
of virtual cancer follow-up. It is essential, however, that
such trials employ robust and consistent measures of
patient satisfaction and acceptability, clinical safety and
cost effectiveness so that powerful evidence on these
outcomes can accumulate.
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